{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T09:04:36Z","timestamp":1769159076399,"version":"3.49.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Theravance"},{"name":"Knopp"},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.iac.2018.06.003","type":"journal-article","created":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T09:51:56Z","timestamp":1537523516000},"page":"639-654","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Airway Eosinophilopoietic and Autoimmune Mechanisms of Eosinophilia in Severe Asthma"],"prefix":"10.1016","volume":"38","author":[{"given":"Anurag","family":"Bhalla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manali","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parameswaran","family":"Nair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.iac.2018.06.003_bib1","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/cea.12480","article-title":"The early history of the eosinophil","volume":"45","author":"Kay","year":"2015","journal-title":"Clin Exp Allergy"},{"issue":"2","key":"10.1016\/j.iac.2018.06.003_bib2","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0140-6736(58)91385-0","article-title":"Treatment of chronic asthma with prednisolone; significance of eosinophils in the sputum","volume":"13","author":"Brown","year":"1958","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.iac.2018.06.003_bib3","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1111\/j.1365-2222.2009.03321.x","article-title":"The definition and diagnosis of asthma","volume":"39","author":"Hargreave","year":"2009","journal-title":"Clin Exp Allergy"},{"issue":"3","key":"10.1016\/j.iac.2018.06.003_bib4","first-page":"144","article-title":"Heterogeneity of bronchitis in airway diseases in tertiary care clinical practice","volume":"18","author":"D'Silva","year":"2011","journal-title":"Can Respir J"},{"issue":"3","key":"10.1016\/j.iac.2018.06.003_bib5","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ccm.2012.05.003","article-title":"How to diagnose and phenotype asthma","volume":"33","author":"Nair","year":"2012","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.iac.2018.06.003_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(17)33311-1","article-title":"Asthma","author":"Papi","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.iac.2018.06.003_bib7","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.iac.2018.06.003_bib8","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jaci.2009.06.029","article-title":"Consistency of sputum eosinophilia in difficult-to-treat asthma: a 5-year follow-up study","volume":"124","author":"van Veen","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/j.iac.2018.06.003_bib9","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S2213-2600(15)00419-1","article-title":"Blood or sputum eosinophils to guide asthma therapy?","volume":"3","author":"Mukherjee","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.iac.2018.06.003_bib10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/00130832-200102000-00014","article-title":"Immune effector functions of eosinophils in allergic airway inflammation","volume":"1","author":"Lacy","year":"2001","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.iac.2018.06.003_bib11","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1365-2222.2008.02958.x","article-title":"Eosinophils: biological properties and role in health and disease","volume":"38","author":"Hogan","year":"2008","journal-title":"Clin Exp Allergy"},{"issue":"3","key":"10.1016\/j.iac.2018.06.003_bib12","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1189\/jlb.0404228","article-title":"Eosinophils function as antigen-presenting cells","volume":"76","author":"Shi","year":"2004","journal-title":"J\u00a0Leukoc Biol"},{"key":"10.1016\/j.iac.2018.06.003_bib13","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3389\/fimmu.2014.00570","article-title":"Eosinophil cytokines, chemokines, and growth factors: emerging roles in immunity","volume":"5","author":"Davoine","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.iac.2018.06.003_bib14","first-page":"206","article-title":"Signalling and degranulation","volume":"vol. 1","author":"Lacy","year":"2013"},{"key":"10.1016\/j.iac.2018.06.003_bib15","series-title":"Eosinophils: methods and protocols","first-page":"111","article-title":"Eosinophil shape change and secretion","author":"Willetts","year":"2014"},{"issue":"11","key":"10.1016\/j.iac.2018.06.003_bib16","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1182\/blood-2012-05-432088","article-title":"Eosinophil extracellular DNA trap cell death mediates lytic release of free secretion-competent eosinophil granules in humans","volume":"121","author":"Ueki","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.iac.2018.06.003_bib17","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1164\/rccm.201311-2069OE","article-title":"Theirs but to die and do: primary lysis of eosinophils and free eosinophil granules in asthma","volume":"189","author":"Persson","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.iac.2018.06.003_bib18","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/all.12206","article-title":"Eosinophil peroxidase in sputum represents a unique biomarker of airway eosinophilia","volume":"68","author":"Nair","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.iac.2018.06.003_bib19","series-title":"Eosinophils in health and disease","first-page":"73","article-title":"Introduction: eosinophilopoiesis","author":"Maltby","year":"2013"},{"issue":"2","key":"10.1016\/j.iac.2018.06.003_bib20","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.chest.2017.01.021","article-title":"Hematopoietic processes in eosinophilic asthma","volume":"152","author":"Salter","year":"2017","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.iac.2018.06.003_bib21","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1146\/annurev.immunol.24.021605.090720","article-title":"The eosinophil","volume":"24","author":"Rothenberg","year":"2006","journal-title":"Annu Rev Immunol"},{"issue":"3 Pt 1","key":"10.1016\/j.iac.2018.06.003_bib22","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0091-6749(94)90195-3","article-title":"The role of adhesion molecules in human eosinophil\u00a0and basophil recruitment","volume":"94","author":"Bochner","year":"1994","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2018.06.003_bib23","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1067\/mai.2003.139","article-title":"Chemokines in asthma: cooperative interaction between chemokines and IL-13","volume":"111","author":"Zimmermann","year":"2003","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2018.06.003_bib24","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S1357-4310(99)01635-4","article-title":"Eotaxin and eosinophil recruitment: implications for human disease","volume":"6","author":"Rankin","year":"2000","journal-title":"Mol Med Today"},{"issue":"12","key":"10.1016\/j.iac.2018.06.003_bib25","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1182\/blood.V79.12.3101.bloodjournal79123101","article-title":"Interleukin-5, eosinophils, and disease","volume":"79","author":"Sanderson","year":"1992","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.iac.2018.06.003_bib26","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1939-4551-7-32","article-title":"Anti-IL5 therapy for asthma and beyond","volume":"7","author":"Mukherjee","year":"2014","journal-title":"World Allergy Organ J"},{"issue":"3","key":"10.1016\/j.iac.2018.06.003_bib27","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1165\/ajrcmb.20.3.3060","article-title":"Immunolocalization of CD34 in nasal polyposis. Effect of topical corticosteroids","volume":"20","author":"Kim","year":"1999","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"3","key":"10.1016\/j.iac.2018.06.003_bib28","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.4049\/jimmunol.164.3.1538","article-title":"Evidence for local eosinophil differentiation within allergic nasal mucosa: inhibition with soluble IL-5 receptor","volume":"164","author":"Cameron","year":"2000","journal-title":"J\u00a0Immunol"},{"issue":"5","key":"10.1016\/j.iac.2018.06.003_bib29","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1165\/ajrcmb.15.5.8918371","article-title":"Increased levels of CD34+ hemopoietic progenitor cells in atopic subjects","volume":"15","author":"Sehmi","year":"1996","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"1","key":"10.1016\/j.iac.2018.06.003_bib30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1165\/ajrcmb.20.1.3449","article-title":"CD34(+)\/interleukin-5Ralpha messenger RNA+ cells in the bronchial mucosa in asthma: potential airway eosinophil progenitors","volume":"20","author":"Robinson","year":"1999","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"6","key":"10.1016\/j.iac.2018.06.003_bib31","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/cea.12695","article-title":"Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma","volume":"46","author":"Sehmi","year":"2016","journal-title":"Clin Exp Allergy"},{"issue":"4","key":"10.1016\/j.iac.2018.06.003_bib32","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/cea.12244","article-title":"Safety and efficacy of an oral CCR3 antagonist in patients with asthma and eosinophilic bronchitis: a randomized, placebo-controlled clinical trial","volume":"44","author":"Neighbour","year":"2014","journal-title":"Clin Exp Allergy"},{"issue":"51","key":"10.1016\/j.iac.2018.06.003_bib33","doi-asserted-by":"crossref","first-page":"pe55","DOI":"10.1126\/scisignal.1.51.pe55","article-title":"Untangling the complex web of IL-4- and IL-13-mediated signaling pathways","volume":"1","author":"Wills-Karp","year":"2008","journal-title":"Sci Signal"},{"issue":"6","key":"10.1016\/j.iac.2018.06.003_bib34","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1172\/JCI5909","article-title":"Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production","volume":"103","author":"Zhu","year":"1999","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"10.1016\/j.iac.2018.06.003_bib35","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11882-004-0057-6","article-title":"Interleukin-13 in asthma pathogenesis","volume":"4","author":"Wills-Karp","year":"2004","journal-title":"Curr Allergy Asthma Rep"},{"issue":"3","key":"10.1016\/j.iac.2018.06.003_bib36","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jaci.2004.11.017","article-title":"Progenitor egress from the bone marrow after allergen challenge: role of stromal cell-derived factor 1alpha and eotaxin","volume":"115","author":"Dorman","year":"2005","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2018.06.003_bib37","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1365-2222.2011.03889.x","article-title":"Interleukin-4 and interleukin-13 prime migrational responses of haemopoietic progenitor cells to stromal cell-derived factor-1\u03b1","volume":"42","author":"Punia","year":"2012","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.iac.2018.06.003_bib38","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.pharmthera.2016.06.009","article-title":"Biologics and the lung: TSLP and other epithelial cell-derived cytokines in asthma","volume":"169","author":"Mitchell","year":"2017","journal-title":"Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.iac.2018.06.003_bib39","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/nm.3300","article-title":"Eosinophils in the spotlight: eosinophilic airway inflammation in nonallergic asthma","volume":"19","author":"Guy","year":"2013","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.iac.2018.06.003_bib40","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.jaci.2009.12.935","article-title":"Increased IL-33 expression by epithelial cells in bronchial asthma","volume":"125","author":"Prefontaine","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2018.06.003_bib41","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaci.2011.08.031","article-title":"Increased expression of immunoreactive thymic stromal lymphopoietin in patients with severe asthma","volume":"129","author":"Shikotra","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.iac.2018.06.003_bib42","doi-asserted-by":"crossref","first-page":"8183","DOI":"10.4049\/jimmunol.174.12.8183","article-title":"Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity","volume":"174","author":"Ying","year":"2005","journal-title":"J\u00a0Immunol"},{"issue":"1","key":"10.1016\/j.iac.2018.06.003_bib43","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1165\/rcmb.2016-0262OC","article-title":"Human bronchial epithelial cell-derived factors from severe asthmatic subjects stimulate eosinophil differentiation","volume":"58","author":"Salter","year":"2017","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"6","key":"10.1016\/j.iac.2018.06.003_bib44","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.jaci.2014.12.1918","article-title":"Thymic stromal lymphopoietin and IL-33 modulate migration of hematopoietic progenitor cells in patients with allergic asthma","volume":"135","author":"Smith","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2018.06.003_bib45","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/ni.1962","article-title":"The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling","volume":"12","author":"Spits","year":"2011","journal-title":"Nat Immunol"},{"issue":"2","key":"10.1016\/j.iac.2018.06.003_bib46","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.coi.2013.02.010","article-title":"Development and function of group 2 innate lymphoid cells","volume":"25","author":"Walker","year":"2013","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2018.06.003_bib47","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jaci.2011.10.036","article-title":"Innate lymphoid cells responding to IL-33 mediate airway hyperreactivity independently of adaptive immunity","volume":"129","author":"Kim","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2018.06.003_bib48","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jaci.2013.05.012","article-title":"IL-33 is more potent than IL-25 in provoking IL-13-producing nuocytes (type 2 innate lymphoid cells) and airway contraction","volume":"132","author":"Barlow","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2018.06.003_bib49","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jaci.2015.05.037","article-title":"Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia","volume":"137","author":"Smith","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.iac.2018.06.003_bib50","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/nm.2737","article-title":"The airway epithelium in asthma","volume":"18","author":"Lambrecht","year":"2012","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.iac.2018.06.003_bib51","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/nri3739","article-title":"The role of airway epithelial cells and innate immune cells in chronic respiratory disease","volume":"14","author":"Holtzman","year":"2014","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.iac.2018.06.003_bib52","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaci.2014.11.037","article-title":"Persistence of asthma requires multiple feedback circuits involving type 2 innate lymphoid cells and IL-33","volume":"136","author":"Christianson","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2018.06.003_bib53","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ccm.2005.10.003","article-title":"Airway smooth muscle as a regulator of immune responses and bronchomotor tone","volume":"27","author":"Lazaar","year":"2006","journal-title":"Clin Chest Med"},{"issue":"6 Suppl","key":"10.1016\/j.iac.2018.06.003_bib54","doi-asserted-by":"crossref","first-page":"S269","DOI":"10.1067\/mai.2002.129429","article-title":"Airway smooth muscle: an immunomodulatory cell","volume":"110","author":"Panettieri","year":"2002","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.iac.2018.06.003_bib55","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/j.1365-2222.2009.03246.x","article-title":"Human airway smooth muscle promotes eosinophil differentiation","volume":"39","author":"Fanat","year":"2009","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"10.1016\/j.iac.2018.06.003_bib56","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/MCP.0000000000000337","article-title":"Glucocortiosteroid subsensitivity and asthma severity","volume":"23","author":"Mukherjee","year":"2017","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.iac.2018.06.003_bib57","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.pharmthera.2015.01.006","article-title":"Heterogeneity in mechanisms influencing glucocorticoid sensitivity: the need for a systems biology approach to treatment of glucocorticoid-resistant inflammation","volume":"150","author":"Keenan","year":"2015","journal-title":"Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.iac.2018.06.003_bib58","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jaci.2017.06.033","article-title":"Sputum autoantibodies in patients with severe eosinophilic asthma","volume":"141","author":"Mukherjee","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1 Pt 1","key":"10.1016\/j.iac.2018.06.003_bib59","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/0091-6749(91)90214-9","article-title":"Effect of steroids on immunoglobulin-induced eosinophil degranulation","volume":"87","author":"Kita","year":"1991","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2018.06.003_bib60","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1164\/rccm.200208-789OC","article-title":"Eosinophil's role remains uncertain as anti\u2013interleukin-5 only partially depletes numbers in asthmatic airway","volume":"167","author":"Flood-Page","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.iac.2018.06.003_bib61","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1164\/rccm.201203-0476OC","article-title":"Asthmatic granulomatosis: a novel disease with asthmatic and granulomatous features","volume":"186","author":"Wenzel","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.iac.2018.06.003_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13223-015-0081-1","article-title":"Therapeutic potential of anti-IL-6 therapies for granulocytic airway inflammation in asthma","volume":"11","author":"Chu","year":"2015","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2018.06.003_bib63","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jaci.2014.11.044","article-title":"MicroRNA-9 regulates steroid-resistant airway hyperresponsiveness by reducing protein phosphatase 2A activity","volume":"136","author":"Li","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2018.06.003_bib64","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jaci.2016.04.038","article-title":"MicroRNA-21 drives severe, steroid-insensitive experimental asthma by amplifying phosphoinositide 3-kinase-mediated suppression of histone deacetylase 2","volume":"139","author":"Kim","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.iac.2018.06.003_bib65","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.jaci.2014.08.022","article-title":"Increased sputum endotoxin levels are associated with an impaired lung function response to oral steroids in asthmatic patients","volume":"134","author":"McSharry","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2018.06.003_bib66","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/all.12831","article-title":"Histone deacetylase activity and recurrent bacterial bronchitis in severe eosinophilic asthma","volume":"71","author":"Zuccaro","year":"2016","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.iac.2018.06.003_bib67","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.jaci.2017.06.037","article-title":"Pathway discovery using transcriptomic profiles in adult-onset severe asthma","volume":"141","author":"Hekking","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"158","key":"10.1016\/j.iac.2018.06.003_bib68","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3389\/fmed.2017.00158","article-title":"Asthma endotypes and an overview of targeted therapy for asthma","volume":"4","author":"Svenningsen","year":"2017","journal-title":"Front Med (Lausanne)"},{"issue":"10","key":"10.1016\/j.iac.2018.06.003_bib69","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.iac.2018.06.003_bib70","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1056\/NEJMoa0805435","article-title":"Mepolizumab for prednisone-dependent asthma with sputum eosinophilia","volume":"360","author":"Nair","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.iac.2018.06.003_bib71","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.iac.2018.06.003_bib72","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.iac.2018.06.003_bib73","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1067\/mai.2003.1382","article-title":"Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics","volume":"111","author":"Menzies-Gow","year":"2003","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2018.06.003_bib74","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1164\/rccm.201707-1323OC","article-title":"Weight-adjusted intravenous reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous mepolizumab","volume":"197","author":"Mukherjee","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"26","key":"10.1016\/j.iac.2018.06.003_bib75","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iac.2018.06.003_bib76","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13223-016-0174-5","article-title":"Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy","volume":"13","author":"Mukherjee","year":"2017","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2018.06.003_bib77","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.4049\/jimmunol.151.3.1235","article-title":"Anti-cytokine antibodies as carrier proteins. Prolongation of in\u00a0vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes","volume":"151","author":"Finkelman","year":"1993","journal-title":"J\u00a0Immunol"},{"issue":"22","key":"10.1016\/j.iac.2018.06.003_bib78","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMoa1105143","article-title":"Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis","volume":"365","author":"Saadoun","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.iac.2018.06.003_bib79","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","article-title":"MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function","volume":"125","author":"Kolbeck","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"25","key":"10.1016\/j.iac.2018.06.003_bib80","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.iac.2018.06.003_bib81","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.jaci.2018.01.008","article-title":"Benralizumab attenuates airway eosinophilia in prednisone-dependent asthma","volume":"141","author":"Sehmi","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.iac.2018.06.003_bib82","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.iac.2018.06.003_bib83","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa1402895","article-title":"Effects of an anti-TSLP antibody on allergen-induced asthmatic responses","volume":"370","author":"Gauvreau","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.iac.2018.06.003_bib84","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S2213-2600(16)30179-5","article-title":"Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial","volume":"4","author":"Gonem","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"10","key":"10.1016\/j.iac.2018.06.003_bib85","doi-asserted-by":"crossref","first-page":"6942","DOI":"10.4049\/jimmunol.181.10.6942","article-title":"Suppression of murine allergic airway disease by IL-2:anti-IL-2 monoclonal antibody-induced regulatory T\u00a0cells","volume":"181","author":"Wilson","year":"2008","journal-title":"J\u00a0Immunol"},{"issue":"24","key":"10.1016\/j.iac.2018.06.003_bib86","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1182\/blood-2014-07-587493","article-title":"Interleukin-5\u2013producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy","volume":"124","author":"Van Gool","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.iac.2018.06.003_bib87","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.4049\/jimmunol.150.7.2717","article-title":"Recombinant soluble murine IL-4 receptor can inhibit or enhance IgE responses in\u00a0vivo","volume":"150","author":"Sato","year":"1993","journal-title":"J\u00a0Immunol"},{"issue":"22","key":"10.1016\/j.iac.2018.06.003_bib88","doi-asserted-by":"crossref","first-page":"4484","DOI":"10.1182\/blood-2012-08-449215","article-title":"IL-7\/anti\u2013IL-7 mAb complexes augment cytokine potency in mice through association with IgG-Fc and by competition with IL-7R","volume":"121","author":"Martin","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.iac.2018.06.003_bib89","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2213-8587(13)70113-X","article-title":"Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1\/2 randomised, double-blind, placebo-controlled trial","volume":"1","author":"Hartemann","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.iac.2018.06.003_bib90","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.jaci.2006.09.007","article-title":"Anti\u2013IL-5 (mepolizumab) therapy for eosinophilic esophagitis","volume":"118","author":"Stein","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.iac.2018.06.003_bib91","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.jaci.2008.02.033","article-title":"Anti\u2013IL-5 (mepolizumab) therapy reduces eosinophil activation ex\u00a0vivo and increases IL-5 and IL-5 receptor levels","volume":"121","author":"Stein","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856118300572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856118300572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:43:51Z","timestamp":1760179431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856118300572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":91,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0889856118300572"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2018.06.003","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Airway Eosinophilopoietic and Autoimmune Mechanisms of Eosinophilia in Severe Asthma","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2018.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}